Reformulation and drop size of apraclonidine hydrochloride

M. J. Vocci, A. L. Robin, J. C. Wahl, P. Mayer, A. Graves, B. York, C. Enger, J. Sutton

Research output: Contribution to journalArticlepeer-review

Abstract

We performed a prospective, double-masked, placebo-controlled, six-period, crossover study in which normal subjects were randomly assigned to treatment and compared three different formulations of apraclonidine hydrochloride (the present commercially available formulation, and formulations with hydroxypropylmethylcellulose or lysolecithin). We also evaluated the efficacy of a 16-μl and 30-μl drop size. The magnitude and duration of decrease in intraocular pressure was comparable for all formulations. Most subjects tolerated all formulations well with only a few reporting any side effects. The best-tolerated formulation was 0.5% apraclonidine hydrochloride delivered with a 16-μl drop size. Dry mouth developed frequently with the commercially available 1% apraclonidine solution. Blurred vision complicated the use of the formulation containing hydroxypropylmethylcellulose. Both dry mouth (P < .05) and blurred vision (P = .004) were statistically significant side effects.

Original languageEnglish (US)
Pages (from-to)154-160
Number of pages7
JournalAmerican journal of ophthalmology
Volume113
Issue number2
DOIs
StatePublished - Jan 1 1992
Externally publishedYes

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Reformulation and drop size of apraclonidine hydrochloride'. Together they form a unique fingerprint.

Cite this